Loading...
Respiratory syncytial virus (RSV) is a common infection that can lead to severe disease, especially in young infants. Two strategies are currently available to provide passive immunity to infants: active immunization of pregnant women (RSVpreF) and monoclonal antibody administration (nirsevimab) to young infants. Both approaches have demonstrated efficacy, particularly against severe disease, but only now has a head-to-head comparison been conducted.
Using a national database, researchers in France studied more than 21,000 infants whose mothers received vaccination with RSVpreF and a matched cohort of infants who received nirsevimab after birth during the 2024–2025 RSV season. Infants were followed for RSV-related hospitalization and …